NCT04240054View on ClinicalTrials.gov

Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myeloma Patients With Renal Insufficiency

PHASE2RecruitingINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

November 2, 2021

Primary Completion Date

December 1, 2029

Study Completion Date

December 1, 2030

Conditions
Multiple Myeloma
Interventions
DRUG

Bortezomib

Bortezomib (1.5 mg/m\^2) subcutaneous on days 1, 8 and 15

DRUG

Isatuximab

Isatuximab (10 mg/kg) IV on days 1, 8, 15 and 22

DRUG

Cyclophosphamide

Cyclophosphamide (250 mg/m\^2) IV on days 1, 8 and 15

DRUG

Dexamethasone

Dexamethasone 20 mg PO or IV (10 mg if \>75 years) on days 1, 2, 8, 9, 15, 16, 22 and 23

Trial Locations (1)

53226

RECRUITING

Froedtert Hospital & the Medical College of Wisconsin, Milwaukee

All Listed Sponsors
lead

Medical College of Wisconsin

OTHER